SEC Form 4 · accession 0000899243-15-002216
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory D Perry
Officer — Chief Financial Officer
Period of report
Aug 3, 2015
Accepted (ET)
Aug 4, 2015 · 4:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $19.58 | Aug 3, 2015 | A | 200,000 | A | — | Aug 3, 2025 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1The stock option award has an exercise price equal to the fair market value of the closing price on the Issuer on the date of grant.
- F225% of the shares of common stock underlying this stock option award will vest on August 3, 2016, with the remaining 75% of the shares of common stock underlying this stock option award vesting thereafter in equal monthly installments through August 3, 2019, subject to the Reporting Person's continued employment with the Issuer.